HUMA insider trading
NasdaqGS HealthcareHumacyte, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Company website: humacyte.com
HUMA insider activity at a glance
FilingIQ has scored 162 insider transactions for HUMA since Aug 26, 2021. The most recent filing in our index is dated May 19, 2026.
Across the full history, 41 open-market purchases
and 90 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on HUMA insider trades is 57.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest HUMA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for HUMA?
- FilingIQ tracks 162 Form 4 insider transactions for HUMA (Humacyte, Inc.), covering filings from Aug 26, 2021 onwards. 4 of those were filed in the last 90 days.
- Are HUMA insiders net buyers or net sellers?
- Across the full Form 4 history for HUMA, 41 transactions (25%) were open-market purchases and 90 (56%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does HUMA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is HUMA in?
- Humacyte, Inc. (HUMA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $179.41M.
Methodology & sources
Every HUMA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.